{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:34Z","timestamp":1789450114281,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1097\/inf.0b013e31826327e4","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T19:02:49Z","timestamp":1340305369000},"page":"1061-1068","source":"Crossref","is-referenced-by-count":54,"title":["Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18\u201336 Months"],"prefix":"10.1097","volume":"31","author":[{"given":"Helen S.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-16-20210202","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/adc.2006.111500","article-title":"Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.","volume":"92","author":"Pace","year":"2007","journal-title":"Arch Dis Child"},{"key":"R8-16-20210202","first-page":"220","article-title":"Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.","volume":"5","author":"Trotter","year":"2002","journal-title":"Commun Dis Public Health"},{"key":"R9-16-20210202","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease.","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"key":"R11-16-20210202","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/CDLI.7.3.390-395.2000","article-title":"Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread.","volume":"7","author":"Jelfs","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","article-title":"Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.","volume":"38","author":"Tondella","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"R14-16-20210202","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"R15-16-20210202","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"R16-16-20210202","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"R17-16-20210202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"R18-16-20210202","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein.","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R22-16-20210202","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R23-16-20210202","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R24-16-20210202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erv.11.50","article-title":"New frontiers in meningococcal vaccines.","volume":"10","author":"Anderson","year":"2011","journal-title":"Expert Rev Vaccines"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006454-201210000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T10:29:52Z","timestamp":1646216992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201210000-00016"}},"subtitle":["A Phase 1 Randomized-controlled Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31826327e4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717950583.793455851","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717950583.793458137","asserted-by":"object"}]},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}